In 2025, respiratory medicine crossed a threshold: biologics entered COPD at scale, fibrosis pipelines delivered differentiated signals, and precision tools began to reshape how patients are selected, monitored, and kept on therapy.
Dive deeper
The year’s storyline: Three Structural Shifts in Respiratory Care in 2025
Biologics broke the COPD barrier
After years of mixed signals, 2025 marked the first sustained entry of biologics into COPD across regions. Approvals and submissions for dupilumab and mepolizumab established eosinophilic COPD as a commercially and clinically viable segment, shifting COPD from a purely inhaler-driven market toward phenotype-led escalation.
Fibrosis pipelines moved beyond “slowing decline”
Idiopathic pulmonary fibrosis and related interstitial lung diseases saw an unusually dense set of positive readouts. Multiple agents demonstrated meaningful effects on forced vital capacity, vascular remodeling, or biomarker-defined pathways, reinforcing investor confidence that IPF is no longer a single-mechanism graveyard but a multi-shot-on-goal space.
Precision delivery and durability became differentiators
Across asthma, cystic fibrosis, bronchiectasis, and pulmonary arterial hypertension, competitive advantage increasingly came from dosing interval, delivery route, and patient burden. Ultra-long-acting biologics, inhaled reformulations, gene and phage therapies, and device innovation all pointed toward the same strategic goal: keep patients stable, adherent, and out of hospital.
Clinical Readouts That Shaped Respiratory Care Management and Practice in 2025
1) Dupilumab (BOREAS / NOTUS, phase 3, COPD)
Reductions in exacerbations of approximately thirty to thirty-four percent, with lung function and quality-of-life improvements sustained to week fifty-two, established dupilumab as the first biologic to clear regulatory hurdles in COPD across multiple geographies.
The data reframed COPD care for patients with type 2 inflammation, forcing payers and clinicians to reconsider escalation algorithms long dominated by triple inhaler therapy.
2) Mepolizumab (MATINEE, phase 3, COPD)
A twenty-one percent reduction in moderate-to-severe exacerbations overall, rising to thirty-one percent in chronic bronchitis subgroups, coupled with a thirty-five percent reduction in emergency visits and hospitalizations, delivered a differentiated positioning for anti–IL-5 therapy in COPD.
Monthly dosing and a well-characterized safety profile lowered adoption friction relative to newer mechanisms.
3) Sotatercept / Winrevair (ZENITH, phase 3, PAH)
A seventy-six percent reduction in major morbidity and mortality events led to early trial termination for efficacy.
Beyond pulmonary arterial hypertension, the result reinforced the commercial value of disease-modifying vascular biology and validated aggressive endpoint selection for late-stage pulmonary trials.
4) Nerandomilast (FIBRONEER-ILD, phase 3)
Slowing of forced vital capacity decline from minus one hundred eighty-three point five milliliters on placebo to minus one hundred fourteen point seven milliliters, with tolerability close to placebo, positioned nerandomilast as a credible next-generation antifibrotic.
Regulatory filings across the United States, Europe, and China underscored its global ambition in progressive pulmonary fibrosis.
5) Brensocatib (phase 3, bronchiectasis)
Significant reductions in pulmonary exacerbations alongside slower lung function decline over fifty-two weeks marked the first convincing late-stage success in non-cystic fibrosis bronchiectasis.
Priority Review without an advisory committee signaled regulatory confidence in a field long starved of approved options.
Approvals, Guidelines and Access Decisions Driving Change in Respiratory Care in 2025
United States: biologics and rare lung disease momentum
FDA approvals for mepolizumab in eosinophilic COPD and brensocatib under Priority Review reshaped treatment expectations in large, underserved populations. Yutrepia gained approval in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, while multiple orphan and RMAT designations accelerated gene-editing and cell therapies in alpha-one antitrypsin deficiency and acute respiratory distress syndrome.
Europe: CFTR dominance and fibrosis expansion
The European Commission and CHMP expanded access to Kaftrio and advanced Alyftrek, extending CFTR modulation to younger patients and non–class I mutations. Fibrosis assets, including nerandomilast, progressed through regulatory pathways, reinforcing Europe as a parallel launch market rather than a lagging one.
Asia-Pacific: firsts and fast followers
Japan and South Korea approved dupilumab as the first biologic for COPD, while China advanced reviews for mepolizumab and multiple inhaled generics and reformulations. These decisions highlighted Asia-Pacific as a biologics growth engine rather than a late adopter, with reimbursement dynamics increasingly aligned to Western standards.
Global access and substitution dynamics
Interchangeable biosimilars, including omalizumab biosimilars, gained regulatory traction, while discontinuations such as Promixin forced managed switching and device retraining. Cost reductions for tuberculosis therapies and expanded respiratory syncytial virus prevention in infants demonstrated how pricing and delivery decisions can rapidly alter population-level impact.
Safety, Tolerability, and Supportive Care Shaping Respiratory Treatment Continuity in 2025
Guardrails around inflammation
As biologics expanded into COPD and asthma-adjacent populations, regulators and clinicians focused on eosinophilia, infection risk, and long-term immunomodulation. Consistent safety profiles across trials reduced hesitation but reinforced the need for baseline biomarker assessment.
Monitoring burden matters
Ultra-long-acting agents and inhaled reformulations reduced clinic visits and infusion time, while post-marketing surveillance for inhalers such as Trelegy Ellipta reassured payers that broader reimbursement would not translate into unexpected safety signals.
Switching risk became operational, not theoretical
Device phase-outs and formulary changes exposed the fragility of adherence when training gaps occur. Successful programs paired drug substitution with structured education, highlighting that access strategy is inseparable from patient support infrastructure.
Adherence as a competitive moat
Once-daily, six-month, or one-time therapies increasingly outperformed on real-world persistence, even when efficacy differences were modest. In 2025, convenience translated directly into market share defense.
Diagnostics, Stratification, and Measurement Enabling Better Matching and Endpoints in Respiratory Care in 2025
Biomarker-driven selection moved into routine practice
Blood eosinophils defined eligibility for COPD biologics, while fractional exhaled nitric oxide reductions of fifty-three percent and rapid FEV1 gains within days helped differentiate next-generation asthma assets.
Imaging and functional tools lowered monitoring burden
Dynamic chest radiography and AI-enabled respiratory monitoring supported longitudinal assessment with fewer clinic visits. In fibrosis, deep-learning imaging and vascular volume metrics complemented forced vital capacity, strengthening mechanistic confidence and payer narratives.
Non-invasive diagnostics enabled earlier intervention
Breath tests for chronic infection, finger-prick antibody assays for rare lung disease, and contactless monitoring applications signaled a shift toward proactive management rather than crisis-driven care.
Catalyst calendar (only timelines explicitly stated)
January–August 2025
- Regulatory decision for brensocatib, with PDUFA date of August 12, 2025
- Ongoing global submissions for nerandomilast
Late 2025
- Top-line data from multiple phase 3 and late phase 2 idiopathic pulmonary fibrosis programs
- Interim biomarker readouts in fibrosis and asthma pipelines
2026
- Phase 3 initiation in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease for inhaled prostacyclin programs
- Phase 3 starts for chronic cough and fibrosis assets following positive phase 2b data
Key 2025 Respiratory Takeaways
In 2025, respiratory medicine shifted decisively toward precision-led, durable control. Biologics crossed into COPD, fibrosis pipelines delivered credible differentiation, and delivery innovation became as strategically important as mechanism. For senior leaders, competitive advantage now sits at the intersection of biology, patient burden, and access execution—not in any single trial result.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 See the fullRespiratory archiveon our research hub page